

On page 56, line 14, after "Fig. 1A", insert -- (SEQ ID NO:1) --
On page 81, line 5, after "Figure 1A", insert -- (SEQ ID NO:1) --
On page 81, line 14, after "Figure 1A", insert -- (SEQ ID NO:1) --
On page 81, line 15, after "Figure 1A", insert -- (SEQ ID NO:1) --
On page 82, line 10, after "see Fig. 1A", insert -- ;SEQ ID NO:1 --
On page 84, line 9, after "Figure 1A", insert -- ;SEQ ID NO:1 --
On page 84, line 11, after "Figure 1A", insert -- ;SEQ ID NO:1 --
On page 84, line 12, after "Figure 1A", insert -- (SEQ ID NO:1) --

IN THE CLAIMS:

Please cancel claim 2 without prejudice.

Please add the following claims:

✓ 22. The Apo-2 ligand polypeptide of claim 1 wherein said polypeptide comprises an N-terminal methionine residue.

✓ 23. The method of claim 21 wherein said Apo-2 ligand polypeptide is infused to said mammal by an implanted pump device.

✓ 24. The method of claim 23 wherein said cancer is colon cancer.

✓ 25. A composition for stimulating or inducing mammalian cancer cell apoptosis comprising a carrier and an effective amount of Apo-2 ligand polypeptide consisting of amino acid residues 91-281 of SEQ ID NO:1.

✓ 26. A method of stimulating or inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to an effective amount of soluble Apo-2 ligand polypeptide consisting of amino acid residues 91-281 of SEQ ID NO:1. --

REMARKS

Claim 2 has been canceled without prejudice, and claims 22-26 have been added. It is believed that no new matter is introduced by these amendments.

The specification has been amended on various pages to use references to particular sequence identifiers where appropriate. The other amendment to the specification relates to the May 19, 1998 publication in the Official Gazette, 1210 OG 74, that the ATCC address has changed. In compliance with 37 CFR 1.809(d), Applicants are hereby correcting the address of the depository as recited in the specification.